Phathom Pharmaceuticals reported a net loss of $21.1 million for the second quarter of 2020. The company resumed patient screening and enrollment in Phase 3 trials for vonoprazan and continued to build its organization. R&D and G&A expenses increased due to clinical trial costs and the buildout of administrative and commercial functions. Cash and cash equivalents were $247.3 million as of June 30, 2020.